Pedro Naranjo-Gonzalez

Madrid, MD 28006, Spain

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 11 publications

Correction to "AI-Driven De Novo Design and Development of Nontoxic DYRK1A Inhibitors".

Correction to "AI-Driven De Novo Design and Development of Nontoxic DYRK1A Inhibitors".

Journal: Journal of medicinal chemistry

Published: December 08, 2025

AI-Driven De Novo Design and Development of Nontoxic DYRK1A Inhibitors.

AI-Driven De Novo Design and Development of Nontoxic DYRK1A Inhibitors.

Journal: Journal of medicinal chemistry

Published: May 03, 2025

Targeting CB2 receptor with a novel antagonist reverses cognitive decline, neurodegeneration and pyroptosis in a TAU-dependent frontotemporal dementia mouse model.

Targeting CB2 receptor with a novel antagonist reverses cognitive decline, neurodegeneration and pyroptosis in a TAU-dependent frontotemporal dementia mouse model.

Journal: Brain, behavior, and immunity

Published: September 23, 2024

Multitarget drugs as potential therapeutic agents for alzheimer's disease. A new family of 5-substituted indazole derivatives as cholinergic and BACE1 inhibitors.

Multitarget drugs as potential therapeutic agents for alzheimer's disease. A new family of 5-substituted indazole derivatives as cholinergic and BACE1 inhibitors.

Journal: Journal of enzyme inhibition and medicinal chemistry

Published: September 02, 2022

New cannabinoid receptor antagonists as pharmacological tool.

New cannabinoid receptor antagonists as pharmacological tool.

Journal: Bioorganic & medicinal chemistry

Published: April 18, 2020

Targeting Cannabinoid Receptor Activation and BACE-1 Activity Counteracts TgAPP Mice Memory Impairment and Alzheimer's Disease Lymphoblast Alterations.

Targeting Cannabinoid Receptor Activation and BACE-1 Activity Counteracts TgAPP Mice Memory Impairment and Alzheimer's Disease Lymphoblast Alterations.

Journal: Molecular neurobiology

Published: May 31, 2019

Indazolylketones as new multitarget cannabinoid drugs.

Indazolylketones as new multitarget cannabinoid drugs.

Journal: European journal of medicinal chemistry

Published: October 24, 2018

Activation of the Cannabinoid Type 2 Receptor by a Novel Indazole Derivative Normalizes the Survival Pattern of Lymphoblasts from Patients with Late-Onset Alzheimer's Disease.

Activation of the Cannabinoid Type 2 Receptor by a Novel Indazole Derivative Normalizes the Survival Pattern of Lymphoblasts from Patients with Late-Onset Alzheimer's Disease.

Journal: CNS drugs

Published: May 08, 2018

Novel Imidazo[4,5-c][1,2,6]thiadiazine 2,2-dioxides as antiproliferative trypanosoma cruzi drugs: Computational screening from neural network, synthesis and in vivo biological properties.

Novel Imidazo[4,5-c][1,2,6]thiadiazine 2,2-dioxides as antiproliferative trypanosoma cruzi drugs: Computational screening from neural network, synthesis and in vivo biological properties.

Journal: European journal of medicinal chemistry

Published: February 01, 2017

Cannabinoid agonists showing BuChE inhibition as potential therapeutic agents for Alzheimer's disease.

Cannabinoid agonists showing BuChE inhibition as potential therapeutic agents for Alzheimer's disease.

Journal: European journal of medicinal chemistry

Published: July 31, 2013

Multitarget cannabinoids as novel strategy for Alzheimer disease.

Multitarget cannabinoids as novel strategy for Alzheimer disease.

Journal: Current Alzheimer research

Published: April 11, 2012

Showing 1-11 of 11

Last Updated: 09/26/2026